Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31851799

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2019 Dec 19
First author
Ray-Coquard I

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2019 Dec 19;381(25):2471-2474. doi: 10.1056/NEJMe1914488.
    note
    Source null
    related pmid
    31851805
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Feb;21(2):e71. doi: 10.1016/S1470-2045(20)30005-X.
    note
    Source null
    related pmid
    31928926
    relationship
    Comment in
  3. citation
    N Engl J Med. 2020 Apr 16;382(16):1573. doi: 10.1056/NEJMc2000644.
    note
    Source null
    related pmid
    32294362
    relationship
    Comment in
  4. citation
    N Engl J Med. 2020 Apr 16;382(16):1573-1574. doi: 10.1056/NEJMc2000644.
    note
    Source null
    related pmid
    32294363
    relationship
    Comment in

Authors and identifiers

  1. name
    Ray-Coquard I
    type
    Author
  2. name
    Pautier P
    type
    Author
  3. name
    Pignata S
    type
    Author
  4. name
    Pérol D
    type
    Author
  5. name
    González-Martín A
    type
    Author
  6. name
    Berger R
    type
    Author
  7. name
    Fujiwara K
    type
    Author
  8. name
    Vergote I
    type
    Author
  9. name
    Colombo N
    type
    Author
  10. name
    Mäenpää J
    type
    Author
  11. name
    Selle F
    type
    Author
  12. name
    Sehouli J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ray-Coquard I
    type
    Author
  2. name
    Pautier P
    type
    Author
  3. name
    Pignata S
    type
    Author
  4. name
    Pérol D
    type
    Author
  5. name
    González-Martín A
    type
    Author
  6. name
    Berger R
    type
    Author
  7. name
    Fujiwara K
    type
    Author
  8. name
    Vergote I
    type
    Author
  9. name
    Colombo N
    type
    Author
  10. name
    Mäenpää J
    type
    Author
  11. name
    Selle F
    type
    Author
  12. name
    Sehouli J
    type
    Author
bibliography ids
  1. nci-bib-dc7301e32050ca5efe86c0d8
book metadata
content sha256
00466766e7bb792091079443ad3471717e99683de68a22671fc6ef4354dd72ae
document type
citation
dois
  1. 10.1056/NEJMoa1911361
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:31851799
immutable id
pubmed:31851799@00466766e7bb792091079443ad3471717e99683de68a22671fc6ef4354dd72ae
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
25
name
The New England journal of medicine
nlm unique id
0255562
pages
2416-2428
volume
381
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2019 Dec 19;381(25):2471-2474. doi: 10.1056/NEJMe1914488.
    note
    Source null
    related pmid
    31851805
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Feb;21(2):e71. doi: 10.1016/S1470-2045(20)30005-X.
    note
    Source null
    related pmid
    31928926
    relationship
    Comment in
  3. citation
    N Engl J Med. 2020 Apr 16;382(16):1573. doi: 10.1056/NEJMc2000644.
    note
    Source null
    related pmid
    32294362
    relationship
    Comment in
  4. citation
    N Engl J Med. 2020 Apr 16;382(16):1573-1574. doi: 10.1056/NEJMc2000644.
    note
    Source null
    related pmid
    32294363
    relationship
    Comment in
outcomes validated
false
pmid
31851799
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
3f45942ab60553987f469f6a5098cee8b40fcd3a24d635fd99702666376837dc
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2019 Dec 19
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31851799/
title
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Preserved source evidence · Not medical advice